SanteChoraleV4, Main, Exploration, bibRecord, 000189

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure.

Identifieur interne : 000189 ( Main/Exploration ); précédent : 000188; suivant : 000190

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure.

Auteurs : Steven Fishbane [États-Unis] ; Nobuyuki Miyawaki

Source :

Kidney international [ 1523-1755 ] ; 2010.

RBID : pubmed:20075952

Descripteurs français

KwdFr :
- Anémie (complications), Anémie (traitement médicamenteux), Anémie (étiologie), Diabète (MeSH), Défaillance cardiaque (induit chimiquement), Défaillance cardiaque (étiologie), Humains (MeSH), Hémoglobines (analyse), Maladie chronique (MeSH), Maladies du rein (complications), Protéines recombinantes (MeSH), Époétine alfa (MeSH), Érythropoïétine (effets indésirables).
MESH :
- analyse : Hémoglobines.
- effets indésirables : Anémie, Maladies du rein, Érythropoïétine.
- induit chimiquement : Défaillance cardiaque.
- traitement médicamenteux : Anémie.
- étiologie : Anémie, Défaillance cardiaque.
- Diabète, Humains, Maladie chronique, Protéines recombinantes, Époétine alfa.

English descriptors

KwdEn :
- Anemia (complications), Anemia (drug therapy), Anemia (etiology), Chronic Disease (MeSH), Diabetes Mellitus (MeSH), Epoetin Alfa (MeSH), Erythropoietin (adverse effects), Heart Failure (chemically induced), Heart Failure (etiology), Hemoglobins (analysis), Humans (MeSH), Kidney Diseases (complications), Recombinant Proteins (MeSH).
MESH :
- chemical , adverse effects : Erythropoietin.
- chemical , analysis : Hemoglobins.
- chemical : Epoetin Alfa, Recombinant Proteins.
- chemically induced : Heart Failure.
- complications : Anemia, Kidney Diseases.
- drug therapy : Anemia.
- etiology : Anemia, Heart Failure.
- Chronic Disease, Diabetes Mellitus, Humans.

Abstract

Anemia is common in chronic kidney disease (CKD). The CHOIR study found increased risk of a composite cardiovascular outcome when anemia was treated with epoetin-alfa to a target hemoglobin level of 13.5 as compared with 11.3 g/dl. Whether this increase applies to all patient subgroups equally is unclear. We discuss an analysis by Szczech and colleagues of the effects of the higher hemoglobin target in CKD patients with diabetes mellitus or congestive heart failure.

DOI: 10.1038/ki.2009.455
PubMed: 20075952

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000194
to stream Main, to step Curation: 000191

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure.</title>
<author><name sortKey="Fishbane, Steven" sort="Fishbane, Steven" uniqKey="Fishbane S" first="Steven" last="Fishbane">Steven Fishbane</name>
<affiliation wicri:level="2"><nlm:affiliation>Winthrop-University Hospital, Mineola, New York, USA. sfishbane@metrorenal.com</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Winthrop-University Hospital, Mineola, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Miyawaki, Nobuyuki" sort="Miyawaki, Nobuyuki" uniqKey="Miyawaki N" first="Nobuyuki" last="Miyawaki">Nobuyuki Miyawaki</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:20075952</idno>
<idno type="pmid">20075952</idno>
<idno type="doi">10.1038/ki.2009.455</idno>
<idno type="wicri:Area/Main/Corpus">000194</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000194</idno>
<idno type="wicri:Area/Main/Curation">000191</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000191</idno>
<idno type="wicri:Area/Main/Exploration">000191</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure.</title>
<author><name sortKey="Fishbane, Steven" sort="Fishbane, Steven" uniqKey="Fishbane S" first="Steven" last="Fishbane">Steven Fishbane</name>
<affiliation wicri:level="2"><nlm:affiliation>Winthrop-University Hospital, Mineola, New York, USA. sfishbane@metrorenal.com</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Winthrop-University Hospital, Mineola, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Miyawaki, Nobuyuki" sort="Miyawaki, Nobuyuki" uniqKey="Miyawaki N" first="Nobuyuki" last="Miyawaki">Nobuyuki Miyawaki</name>
</author>
</analytic>
<series><title level="j">Kidney international</title>
<idno type="eISSN">1523-1755</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anemia (complications)</term>
<term>Anemia (drug therapy)</term>
<term>Anemia (etiology)</term>
<term>Chronic Disease (MeSH)</term>
<term>Diabetes Mellitus (MeSH)</term>
<term>Epoetin Alfa (MeSH)</term>
<term>Erythropoietin (adverse effects)</term>
<term>Heart Failure (chemically induced)</term>
<term>Heart Failure (etiology)</term>
<term>Hemoglobins (analysis)</term>
<term>Humans (MeSH)</term>
<term>Kidney Diseases (complications)</term>
<term>Recombinant Proteins (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Anémie (complications)</term>
<term>Anémie (traitement médicamenteux)</term>
<term>Anémie (étiologie)</term>
<term>Diabète (MeSH)</term>
<term>Défaillance cardiaque (induit chimiquement)</term>
<term>Défaillance cardiaque (étiologie)</term>
<term>Humains (MeSH)</term>
<term>Hémoglobines (analyse)</term>
<term>Maladie chronique (MeSH)</term>
<term>Maladies du rein (complications)</term>
<term>Protéines recombinantes (MeSH)</term>
<term>Époétine alfa (MeSH)</term>
<term>Érythropoïétine (effets indésirables)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Erythropoietin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Hemoglobins</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Epoetin Alfa</term>
<term>Recombinant Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Hémoglobines</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Heart Failure</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Anemia</term>
<term>Kidney Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Anemia</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anémie</term>
<term>Maladies du rein</term>
<term>Érythropoïétine</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Anemia</term>
<term>Heart Failure</term>
</keywords>
<keywords scheme="MESH" qualifier="induit chimiquement" xml:lang="fr"><term>Défaillance cardiaque</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Anémie</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Anémie</term>
<term>Défaillance cardiaque</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Chronic Disease</term>
<term>Diabetes Mellitus</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Diabète</term>
<term>Humains</term>
<term>Maladie chronique</term>
<term>Protéines recombinantes</term>
<term>Époétine alfa</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Anemia is common in chronic kidney disease (CKD). The CHOIR study found increased risk of a composite cardiovascular outcome when anemia was treated with epoetin-alfa to a target hemoglobin level of 13.5 as compared with 11.3 g/dl. Whether this increase applies to all patient subgroups equally is unclear. We discuss an analysis by Szczech and colleagues of the effects of the higher hemoglobin target in CKD patients with diabetes mellitus or congestive heart failure.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20075952</PMID>
<DateCompleted><Year>2010</Year>
<Month>04</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1523-1755</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>77</Volume>
<Issue>3</Issue>
<PubDate><Year>2010</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Kidney international</Title>
</Journal>
<ArticleTitle>Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure.</ArticleTitle>
<Pagination><MedlinePgn>175-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/ki.2009.455</ELocationID>
<Abstract><AbstractText>Anemia is common in chronic kidney disease (CKD). The CHOIR study found increased risk of a composite cardiovascular outcome when anemia was treated with epoetin-alfa to a target hemoglobin level of 13.5 as compared with 11.3 g/dl. Whether this increase applies to all patient subgroups equally is unclear. We discuss an analysis by Szczech and colleagues of the effects of the higher hemoglobin target in CKD patients with diabetes mellitus or congestive heart failure.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fishbane</LastName>
<ForeName>Steven</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Winthrop-University Hospital, Mineola, New York, USA. sfishbane@metrorenal.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Miyawaki</LastName>
<ForeName>Nobuyuki</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Kidney Int</MedlineTA>
<NlmUniqueID>0323470</NlmUniqueID>
<ISSNLinking>0085-2538</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>11096-26-7</RegistryNumber>
<NameOfSubstance UI="D004921">Erythropoietin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>64FS3BFH5W</RegistryNumber>
<NameOfSubstance UI="D000068817">Epoetin Alfa</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Kidney Int. 2010 Feb;77(3):239-46</RefSource>
<PMID Version="1">19890274</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000740" MajorTopicYN="N">Anemia</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000068817" MajorTopicYN="N">Epoetin Alfa</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004921" MajorTopicYN="N">Erythropoietin</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007674" MajorTopicYN="N">Kidney Diseases</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year>
<Month>1</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2010</Year>
<Month>1</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>5</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">20075952</ArticleId>
<ArticleId IdType="pii">S0085-2538(15)54237-3</ArticleId>
<ArticleId IdType="doi">10.1038/ki.2009.455</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>État de New York</li>
</region>
</list>
<tree><noCountry><name sortKey="Miyawaki, Nobuyuki" sort="Miyawaki, Nobuyuki" uniqKey="Miyawaki N" first="Nobuyuki" last="Miyawaki">Nobuyuki Miyawaki</name>
</noCountry>
<country name="États-Unis"><region name="État de New York"><name sortKey="Fishbane, Steven" sort="Fishbane, Steven" uniqKey="Fishbane S" first="Steven" last="Fishbane">Steven Fishbane</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SanteChoraleV4/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000189 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000189 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SanteChoraleV4
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:20075952
   |texte=   Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:20075952" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a SanteChoraleV4

This area was generated with Dilib version V0.6.37.
Data generation: Sat Oct 10 10:36:24 2020. Site generation: Sat Oct 10 10:37:38 2020

	Serveur d'exploration sur le chant choral et la santé
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le chant choral et la santé

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure.

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki